Anzeige
Mehr »
Login
Samstag, 14.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Gold bricht wieder Rekorde: Warum dieser dritte Anstieg anders ist und wie man profitieren kann
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
510 Leser
Artikel bewerten:
(2)

Central Nervous System Therapeutics Market size worth $ 168.43 Billion, Globally, by 2028 at 9.05% CAGR: Verified Market Research

An increase in the number of patients suffering CNS disorders such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, and others, is likely to be the factor to lead Central Nervous System Therapeutics Market.

JERSEY CITY, N.J., March 23, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Central Nervous System Therapeutics Market" By Disease (Neurovascular Diseases, Trauma, Mental Health), By Drug Class (Analgesics, Nervous System Drugs, Anesthetics), and By Geography. According to Verified Market Research, the Global Central Nervous System Therapeutics Market size was valued at USD 84.24 Billion in 2020 and is projected to reach USD 168.43 Billion by 2028, growing at a CAGR of 9.05% from 2021 to 2028.

Verified_Market_Research_Logo

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=221347

Browse in-depth TOC on "Central Nervous System Therapeutics Market"

202 - Pages

126 - Tables

37 - Figures

Global Central Nervous System Therapeutics Market Overview

Advancements in diagnostics, treatments, and drug discovery methodologies are driving the growth of the Central Nervous System Therapeutics Market. Furthermore, the rising demand for effective CNS therapeutic choices pushes big pharmaceutical companies to engage in research and development, paving the way for future growth. Furthermore, increased awareness of psychiatric diseases, an increase in the frequency of mental illness and lifestyle-related CNS disorders, and an increase in the elderly population all contribute to the global market's growth. Since the last several years, the rate of acute psychological distress among teenagers and young adults has been on the rise, fueling demand for CNS therapies around the world.

However, strict & extended drug approval procedures and increasing prices of new treatments are likely to restrict the growth of the Central Nervous System Therapeutics Market. According to the WHO, dementia affects 50 million people worldwide, with approximately 60% of them residing in low- and middle-income countries. As per the Parkinson's Foundation, there are 2.8 million people with multiple sclerosis and ten million people with Parkinson's disease in the world. These disorders have a limited number of therapeutic choices. Currently, five authorized medications are commonly used to treat Alzheimer's disease, and 146 clinical studies in Phases 1, 2, and 3 are enrolling participants. Agents capsules for Parkinson's disease when a patient's meds aren't functioning and Zeposia capsules for relapsing types of multiple sclerosis were recently approved by the FDA.

According to Alzheimer's Europe, the European Union's dementia population is expected to be at 7.8 million people. Furthermore, the Harvard NeuroDiscovery Center predicts that almost 12 million Americans will be affected by neurodegenerative disorders in 30 years if no action is taken. As a result of the rising prevalence of these diseases, the medication development pipeline, and the potential of this segment, clinical trials, product launches, and strategic alliances are becoming more common.

Key Developments

  • April 2021, The National Medical Products Administration (NMPA) has approved Biogen's TECFIDERA (dimethyl fumarate) to treat relapsed multiple sclerosis, allowing the company to extend its presence in China.
  • April 2021, Patients are still being recruited for phase III clinical studies of aripiprazole to treat Alzheimer's dementia, according to Otsuka and Lundbeck.
  • June 2021, GSK and iTeos Therapeutics have announced an agreement to develop and commercialize EOS-448, an anti-TIGIT monoclonal antibody that will enable novel next-generation immuno-oncology combinations.

Key Players

The major players in the market are Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck KGaA, AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, and GlaxoSmithKline PLC.

Verified Market Research has segmented the Global Central Nervous System Therapeutics Market On the basis of Disease, Drug Class, and Geography.

  • Central Nervous System Therapeutics Market, By Disease
    • Neurovascular Diseases
    • Trauma
    • Mental Health
    • Degenerative Diseases
    • Infectious Diseases
    • Cancer
    • Other Infectious Diseases
  • Central Nervous System Therapeutics Market, By Drug Class
    • Analgesics
    • Nervous System Drugs
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Other Drug Classes
  • Central Nervous System Therapeutics Market by Geography
    • North America
      • U.S
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia Pacific
    • ROW
      • Middle East & Africa
      • Latin America

Browse Related Reports:

Regenerative Medicine Market By Therapy (Tissue Engineering, Immunotherapy, Gene Therapy), By Product (Cell-Based Products and Acellular Products), By Application (Central Nervous System Diseases, Oncology, Diabetes), By Geography, Forecast, 2021-2028

Intraoperative Radiation Therapy Market By Technology (Electron IORT & Intraoperative Brachytherapy), By Product and Service (Products, Systems/Accelerators, Applicators & Afterloaders, Treatment Planning Systems, Accessories, & Services), By Application (Breast Cancer, Brain Tumor, & Lung Cancer), By Geography, Forecast, 2021-2028

Neurostimulation Devices Market By Devices Type (Implantable Devices, Vagus Nerve Stimulators, Spinal Cord Stimulators, Deep Brain Stimulators), By Application (Parkinson's disease, Epilepsy, Depression, Dystonia), By Geography, Forecast, 2021-2028

Neurorehabilitation Devices Market By Product (Brain-computer Interface, Neurorobotic Systems, Brain Stimulators, Wearable Devices), By Brain Stimulators (Non-invasive Stimulators and Invasive Stimulators), By Application (Brain & Spinal Cord Injury, Stroke, Multiple Sclerosis, Parkinson's Disease), By Geography, Forecast, 2021-2028

Top 7 Cardioverter Defibrillator Companies offering life saving medical equipment globally

Visualize Central Nervous System Therapeutics Market using Verified Market Intelligence:-:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us

Mr. Edwyne Fernandes
Verified Market Research
US: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1315349/Verified_Market_Research_Logo.jpg

© 2022 PR Newswire
Gold - Die besten Aktien für den nächsten Preisschub

Steigen Sie jetzt ein und nutzen Sie die einmalige Chance, die Ihnen der nächste Goldpreisschub bietet!

Dieser Aktienreport stellt die besten Aktien für den kommenden Goldpreisanstieg vor. Zur ausgewogenen Diversifikation eines Depots sind Engagements in Gold oder Aktien von Goldproduzenten unerlässlich. Die letzten Monate haben gezeigt, dass Goldinvestments nicht nur stabilisierend sein können, sondern auch erhebliche Gewinne ermöglichen. Nach einer Konsolidierungsphase bieten sich nun wieder spannende Einstiegsmöglichkeiten.

Nutzen Sie diese Chance!

Fordern Sie jetzt den brandneuen Spezialreport an und erfahren Sie, welche Goldaktien das größte Potenzial haben. Dieser Report ist 100 % kostenlos und hilft Ihnen, die besten Investments im Goldsektor zu identifizieren.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Um Ihnen den Report zusenden zu können, geben Sie einfach Ihre E-Mail-Adresse hier ein. Sie erhalten umgehend Zugang zu Ihrem PDF-Report. Dies ist für Sie vollkommen kostenlos und unverbindlich.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.